SCHEMBL3340285

SCHEMBL3340285

Cc1cc(-c2cc(-c3ccncc3)nc(=O)[nH]2)ccc1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 6/20 0.70
CDC7 O00311 5/20 0.70
PIM1 P11309 3/20 0.70
CSNK2A1 P68400 2/20 0.70
CSNK2A2 P19784 1/20 0.70
CLK1 P49759 1/20 0.70
CSNK2B P67870 1/20 0.70
CSNK2A3 Q8NEV1 1/20 0.70
CXCL12 P48061 1/20 0.49
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
FGFR1 P11362 2/20 0.38
MAPK13 O15264 1/20 0.38
DAPK3 O43293 1/20 0.38
ROCK2 O75116 1/20 0.38
PRKD3 O94806 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13305082 0.95 CDC7 (0.79) GSK3BCDC7PIM1CSNK2A1CSNK2A2
SCHEMBL385819 0.84 CDC7 (0.82) GSK3BCDC7PIM1CSNK2A1CSNK2A2
SCHEMBL386108 0.84 CDC7 (0.82) GSK3BCDC7PIM1CSNK2A1CSNK2A2
SCHEMBL19782832 0.84 CXCL12 (0.71) GSK3BCDC7PIM1CSNK2A1CSNK2A2
SCHEMBL10165675 0.83 CDC7 (1.00) GSK3BCDC7PIM1CSNK2A1CSNK2A2
SCHEMBL22065542 0.83 CXCL12 (0.69) GSK3BCDC7PIM1CSNK2A1CSNK2A2
SCHEMBL386208 0.82 CDC7 (0.71) GSK3BCDC7PIM1CSNK2A1CSNK2A2
SCHEMBL385566 0.82 CDC7 (0.79) GSK3BCDC7PIM1CSNK2A1CSNK2A2
SCHEMBL383356 0.82 CDC7 (0.79) GSK3BCDC7PIM1CSNK2A1CSNK2A2
SCHEMBL11915777 0.82 CDC7 (0.79) GSK3BCDC7PIM1CSNK2A1CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074114-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2013-03-06 EP claimed
US-8324231-B2 Pyrimidinones as casein kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-12-04 US claimed
EP-2074114-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2013-03-06 EP disclosed
US-8324231-B2 Pyrimidinones as casein kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-12-04 US disclosed
US-20100144770-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. (US) 2010-06-10 US disclosed
EP-2074114-A1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS Exelixis, Inc. (US) 2009-07-01 EP disclosed
WO-2008143759-A1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2008-11-27 WO disclosed
WO-2008143759-A1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144770-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators CSNK2A1, CSNK2A2, CSNK1A1 GSK3B 422/4885CDC7 532/4885PIM1 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.